{"id":"montanide-isa-51-vg","safety":{"commonSideEffects":[{"rate":"null","effect":"Local reaction"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:07:08.716928","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the immune system to produce a stronger response to the vaccine antigens, potentially leading to improved protection against diseases.","oneSentence":"Montanide ISA 51 VG is an adjuvant used to enhance the immune response to vaccines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:04.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy"}]},"_fixedFields":["pubmed(21)"],"trialDetails":[{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07169617","phase":"PHASE2","title":"Testing the SurVaxM Vaccine for Lung Cancer Prevention","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-25","conditions":"Lung Carcinoma","enrollment":80},{"nctId":"NCT06692959","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2025-06-16","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT06789198","phase":"PHASE1","title":"Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-07-08","conditions":"Fibrolamellar Hepatocellular Carcinoma (FLC)","enrollment":20},{"nctId":"NCT07373301","phase":"PHASE2","title":"Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia","status":"NOT_YET_RECRUITING","sponsor":"Malaria Vaccine and Drug Development Center","startDate":"2026-01-19","conditions":"Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention","enrollment":72},{"nctId":"NCT05155254","phase":"PHASE3","title":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"IO Biotech","startDate":"2022-05-17","conditions":"Metastatic Melanoma, Unresectable Melanoma","enrollment":407},{"nctId":"NCT06605963","phase":"PHASE2","title":"PPV-06 Vaccine in Inflammatory Knee Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Peptinov SAS","startDate":"2025-12","conditions":"Osteoarthritis, Knee","enrollment":204},{"nctId":"NCT02264236","phase":"PHASE1, PHASE2","title":"Vaccination of Advanced-Stage Lung Cancer Patients","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2015-10","conditions":"Lung Neoplasms","enrollment":""},{"nctId":"NCT02818426","phase":"PHASE1, PHASE2","title":"Universal Cancer Peptide-based Vaccination in Metastatic NSCLC","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-04-20","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT06094101","phase":"PHASE1, PHASE2","title":"Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-09-19","conditions":"Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma","enrollment":30},{"nctId":"NCT05937295","phase":"PHASE1","title":"FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-09-26","conditions":"Fibrolamellar Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT02938442","phase":"PHASE1, PHASE2","title":"Vaccination of Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2019-01-25","conditions":"Triple Negative Breast Cancer, Breast Neoplasms","enrollment":16},{"nctId":"NCT02229084","phase":"PHASE1, PHASE2","title":"Vaccination of High Risk Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2015-01-14","conditions":"Breast Cancer, Breast Neoplasms","enrollment":58},{"nctId":"NCT03003195","phase":"PHASE2","title":"The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2021-03-01","conditions":"Neoplasms by Site, Metastatic Cancer","enrollment":""},{"nctId":"NCT05898828","phase":"PHASE1, PHASE2","title":"Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-02","conditions":"Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm","enrollment":""},{"nctId":"NCT04447898","phase":"PHASE1","title":"Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine","status":"COMPLETED","sponsor":"Peptinov SAS","startDate":"2021-02-18","conditions":"Knee Osteoarthritis","enrollment":24},{"nctId":"NCT05014607","phase":"","title":"Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients","status":"AVAILABLE","sponsor":"University Hospital Tuebingen","startDate":"","conditions":"Cancer","enrollment":""},{"nctId":"NCT05280314","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","status":"RECRUITING","sponsor":"IO Biotech","startDate":"2023-12-21","conditions":"Melanoma, Squamous Cell Carcinoma of Head and Neck","enrollment":60},{"nctId":"NCT06252584","phase":"PHASE1","title":"Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2024-05-02","conditions":"Acute Myeloid Leukemia, Adult","enrollment":20},{"nctId":"NCT04864418","phase":"PHASE1","title":"AST-021p Study in Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Aston Sci. Inc.","startDate":"2021-06-09","conditions":"Advanced Cancer","enrollment":19},{"nctId":"NCT01176474","phase":"PHASE1","title":"Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2010-08-13","conditions":"Melanoma (Skin)","enrollment":73},{"nctId":"NCT00071981","phase":"PHASE2","title":"Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-05-09","conditions":"Melanoma (Skin)","enrollment":175},{"nctId":"NCT05876195","phase":"NA","title":"KLH Challenge to Explore the Human Immune Response","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-03-01","conditions":"Immune Response","enrollment":39},{"nctId":"NCT01176461","phase":"PHASE1","title":"Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2010-08-04","conditions":"Melanoma (Skin)","enrollment":127},{"nctId":"NCT00616941","phase":"PHASE1","title":"Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2008-03","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":28},{"nctId":"NCT01810016","phase":"PHASE1","title":"NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2014-01-24","conditions":"Unresectable or Metastatic Melanoma","enrollment":8},{"nctId":"NCT00972309","phase":"PHASE1","title":"A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-05-11","conditions":"Prostate Specific Antigens, Prostate Neoplasms","enrollment":41},{"nctId":"NCT00299728","phase":"PHASE1","title":"NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2006-03-21","conditions":"Tumors","enrollment":22},{"nctId":"NCT02334735","phase":"PHASE2","title":"A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence","status":"COMPLETED","sponsor":"Nina Bhardwaj","startDate":"2015-07-01","conditions":"Melanoma","enrollment":36},{"nctId":"NCT00084656","phase":"PHASE2","title":"Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-05-31","conditions":"Intraocular Melanoma, Melanoma (Skin)","enrollment":77},{"nctId":"NCT04546841","phase":"PHASE1","title":"Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2020-11-27","conditions":"COVID-19 Vaccine","enrollment":36},{"nctId":"NCT01312389","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2011-04","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":3},{"nctId":"NCT02293707","phase":"PHASE2","title":"A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Laboratoires Leurquin Mediolanum","startDate":"2014-11","conditions":"Prostate Cancer","enrollment":99},{"nctId":"NCT01989572","phase":"PHASE3","title":"Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-02-23","conditions":"Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma","enrollment":815},{"nctId":"NCT02665364","phase":"PHASE2","title":"Phase IIb Study of IFN-K in Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Neovacs","startDate":"2015-09-23","conditions":"Systemic Lupus Erythematosus","enrollment":185},{"nctId":"NCT02754362","phase":"PHASE2","title":"A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-11","conditions":"Glioblastoma, Glioma","enrollment":""},{"nctId":"NCT01390064","phase":"PHASE1","title":"Vaccination of High Risk Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2011-07","conditions":"Stage IV Breast Cancer","enrollment":6},{"nctId":"NCT00365937","phase":"PHASE1, PHASE2","title":"Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2006-08","conditions":"Melanoma","enrollment":19},{"nctId":"NCT01748747","phase":"EARLY_PHASE1","title":"Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-10","conditions":"Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma","enrollment":30},{"nctId":"NCT00415857","phase":"PHASE2","title":"Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Leukemia","enrollment":5},{"nctId":"NCT01702792","phase":"PHASE1","title":"Derivation of Tumor Specific Hybridomas","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2014-01","conditions":"Glioblastoma","enrollment":1},{"nctId":"NCT01842139","phase":"PHASE1","title":"Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-12-05","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":7},{"nctId":"NCT01079741","phase":"PHASE1, PHASE2","title":"Safety Study of Adjuvant Vaccine to Treat Melanoma Patients","status":"COMPLETED","sponsor":"Nina Bhardwaj","startDate":"2010-09","conditions":"Melanoma","enrollment":34},{"nctId":"NCT00000105","phase":"","title":"Vaccination With Tetanus and KLH to Assess Immune Responses.","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-07","conditions":"Cancer","enrollment":112},{"nctId":"NCT00019682","phase":"PHASE3","title":"Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-12","conditions":"Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma","enrollment":185},{"nctId":"NCT02526316","phase":"PHASE1","title":"Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers","status":"COMPLETED","sponsor":"Oryx GmbH & Co. KG","startDate":"2015-06","conditions":"HPV-induced Cancers","enrollment":11},{"nctId":"NCT01264731","phase":"PHASE1","title":"Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2011-01","conditions":"Melanoma","enrollment":4},{"nctId":"NCT00977145","phase":"PHASE1","title":"Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma","status":"TERMINATED","sponsor":"Craig L Slingluff, Jr","startDate":"2009-11","conditions":"Melanoma","enrollment":11},{"nctId":"NCT01846143","phase":"PHASE1","title":"Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies","status":"COMPLETED","sponsor":"Craig L Slingluff, Jr","startDate":"2013-05","conditions":"Melanoma","enrollment":15},{"nctId":"NCT00935545","phase":"PHASE1","title":"Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-07","conditions":"Tumors, Central Nervous System","enrollment":15},{"nctId":"NCT01095848","phase":"PHASE1","title":"A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer","status":"COMPLETED","sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","startDate":"2010-03","conditions":"Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms","enrollment":23},{"nctId":"NCT00923195","phase":"PHASE2","title":"Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12","conditions":"Melanoma, Skin Cancer","enrollment":4},{"nctId":"NCT01008527","phase":"PHASE1","title":"Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-10","conditions":"Melanoma","enrollment":22},{"nctId":"NCT01461148","phase":"PHASE1, PHASE2","title":"Vaccination Against MSI Colorectal Cancer","status":"COMPLETED","sponsor":"Oryx GmbH & Co. KG","startDate":"2011-08","conditions":"Colorectal Cancer","enrollment":22},{"nctId":"NCT01462838","phase":"PHASE1, PHASE2","title":"Immune Therapy of HPV-induced Cancers","status":"COMPLETED","sponsor":"Oryx GmbH & Co. KG","startDate":"2011-08","conditions":"HPV-induced Cancers","enrollment":26},{"nctId":"NCT00089063","phase":"PHASE2","title":"Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-06","conditions":"Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma","enrollment":40},{"nctId":"NCT01989559","phase":"PHASE1","title":"Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma","enrollment":30},{"nctId":"NCT00821652","phase":"PHASE1","title":"Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination","status":"COMPLETED","sponsor":"Nina Bhardwaj","startDate":"2009-02","conditions":"Tumors","enrollment":26},{"nctId":"NCT00085189","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2004-05","conditions":"Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma","enrollment":42},{"nctId":"NCT01012102","phase":"PHASE1","title":"EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-04","conditions":"Advanced Solid Tumors","enrollment":104},{"nctId":"NCT00499577","phase":"PHASE1, PHASE2","title":"Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland Greenebaum Cancer Center","startDate":"2006-12","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":56},{"nctId":"NCT00454168","phase":"PHASE3","title":"Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission","status":"UNKNOWN","sponsor":"The Vaccine Company","startDate":"2005-05","conditions":"Leukemia","enrollment":244},{"nctId":"NCT00513578","phase":"PHASE2","title":"Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome","status":"UNKNOWN","sponsor":"The Vaccine Company","startDate":"2007-01","conditions":"Myelodysplastic Syndromes","enrollment":30},{"nctId":"NCT00357461","phase":"PHASE2","title":"Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2006-05","conditions":"Melanoma (Skin)","enrollment":""},{"nctId":"NCT00109811","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-03","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer","enrollment":32},{"nctId":"NCT00004918","phase":"PHASE1, PHASE2","title":"Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-12","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia","enrollment":69},{"nctId":"NCT00273910","phase":"PHASE2","title":"Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-01","conditions":"High-Risk Melanoma","enrollment":104},{"nctId":"NCT01010737","phase":"PHASE1, PHASE2","title":"A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2009-09","conditions":"Influenza","enrollment":60},{"nctId":"NCT00428077","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-10","conditions":"Leukemia","enrollment":4}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ATRIAL FIBRILLATION"},{"count":2,"reaction":"PNEUMONIA"},{"count":2,"reaction":"PNEUMONITIS"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":21,"recentPublications":[{"date":"2026 Feb","pmid":"41547362","title":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","journal":"The Lancet. Haematology"},{"date":"2024","pmid":"39469638","title":"AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.","journal":"Frontiers in oncology"},{"date":"2024","pmid":"39252947","title":"iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.","journal":"Frontiers in oncology"},{"date":"2023","pmid":"37720232","title":"Mucosal and cellular immune responses elicited by nasal and intramuscular inoculation with ASFV candidate immunogens.","journal":"Frontiers in immunology"},{"date":"2022 Jul 21","pmid":"35890409","title":"Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.","journal":"Pharmaceutics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Montanide ISA 51","NSC 737063"],"phase":"phase_3","status":"active","brandName":"Montanide ISA 51 VG","genericName":"Montanide ISA 51 VG","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Montanide ISA 51 VG is an adjuvant used to enhance the immune response to vaccines. Used for Cancer immunotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}